

Figure S1: The representative FACS plots of sorted T cells (A), B cells(A), and NK cells (B), macrophages (C), and DCs (D) of mice.




Figure S2: The mean intensity of CXCL13 in T cells and macrophages from mock-mice and infected mice.




Figure S3: The mRNA expression of CXCL13 in BMDMs at 12, 24, 36, and 48 hpi.




Figure S4: The cell viability of BMDMs, BMDMs with IL-10R blocker treatment, BMDMs with isotype antibody treatment, and IL-10<sup>-/-</sup> BMDMs.




Figure S5: The cell viability of BMDMs, BMDM with BAY treatment, and BMDM with Ruxo treatment.




Figure S6: The FMDV RNA levels in BMDMs (A) and in sera of mice (B).




Figure S7: The TNF- $\alpha$ , IL-6, and IFN- $\alpha$  concentrations of the supernatant from BMDMs (Mock) and BMDMs infected with FMDV were measured by ELISA.